Brazil's Anvisa Approves Migraine Prevention Drug for Adults

Brazil's health regulator Anvisa approved a new medication for migraine prevention in adults with at least four monthly episodes. The approval expands treatment options in Brazil but does not signal a major shift in global health policy. Market impact is limited to the pharmaceutical sector.